Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion
The nonprofit biotech evaluates potential therapies based on unmet medical need, clinical evidence of safety and efficacy, and the compatibility of institutional partners. Its funding model combines initial seed investment with commercial revenue and non-traditional funding sources. The post Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion appeared first…
The Orphan Therapeutics Accelerator (OTXL) has acquired its first gene therapy, OTXL-101, for ornithine transcarbamylase deficiency (OTCD), a rare, X-linked metabolic disorder. This marks a new chapter for the nonprofit biotech, which aims to utilize tax and other incentives to "liberate and reininitiate development of shelved therapies for rare and ultra rare conditions."
OTXL is part of a four-pronged approach targeting shelved cell and gene therapies, alongside the Orphan ClinDevNet, Orphan Therapies, and CGTxchange. OTXL-101, originally known as AAVLK03hOTC, was developed through a collaboration between Paul Gissen, Ian Alexander, and their respective teams at University College London and Children’s Medical Research Institute.
The therapy employs a liver-targeted adeno-associated virus vector to deliver a functional OTC gene, restoring urea cycle activity in children and adolescents with OTCD. Preliminary results from the first patient treatment, presented at the 2025 ASGCT annual meeting, show promising outcomes, including the patient being taken off Ravicti and a restricted diet.
OTXL-101 has received orphan drug designations in the U.S. and EU, as well as a rare pediatric disease designation in the U.S.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
